ArticleAnnals of surgical oncology2026
Role of Palliative Cytoreductive Surgery for Patients with Incompletely Resectable Peritoneal Carcinomatosis from Lower Gastrointestinal Cancers.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Should Oophorectomy be Routine in Cytoreductive Surgery for Colorectal Cancer-Related Peritoneal Carcinomatosis?Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeritoneal carcinomatosis from lower gastrointestinal malignancies causes debilitating intra-abdominal complications, including bowel obstruction, ascites, and biliary/ureteral obstruction. Guidelines addressing palliative cytoreductive surgery (CRS) in patient's ineligible for curative resection remain limited.
methodsPatients who underwent CRS for appendiceal cancer (AC)- or colorectal cancer (CRC)-related carcinomatosis not amenable to complete cytoreduction at one referral center (2004-2025) were retrospectively reviewed. Tumor grade was dichotomized into low- (well- and well-to-moderately differentiated ACs) versus high-grade (moderately or poorly differentiated/signet ring ACs, all CRCs). Descriptive statistics summarize patient demographics. Carcinomatosis-related complication-free (CRCFS), obstruction-free (OFS), ascites-free (AFS), and overall survival (OS) were estimated by using the Kaplan-Meier method.
resultsA total of 131 patients underwent palliative CRS. The most common reasons for incomplete cytoreduction were high tumor burden/multiple unresectable areas 62 (47%), portal 20 (15%), small bowel 19 (14%), or pelvic 17 (13%) disease. Common palliative procedures included omentectomy 86 (66%), hyperthermic intraperitoneal chemotherapy 63 (48%), bowel resection 63 (48%), gastrostomy tube/gastropexy 60 (46%), and intestinal bypass 27 (20%). Twenty-two (17%) patients had major complications, and median length of stay was 11 days (IQR 9-14). Median CRCFS, OFS, AFS, and OS were 11, 16, 62, and 13 months for high-grade versus 36, NR, NR, and 37 months for low-grade tumors. The strongest predictor of shortened CRCFS, OFS, AFS, and OS was high-grade histology.
conclusionsPalliative CRS for incompletely resectable carcinomatosis is associated with prolonged OFS and AFS for patients with low-grade histology. Palliative surgical intervention should be considered in carefully selected patients.
Indexed as
Identifiers
42547753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.